more patients on the new anticoagulant dabigatran (Pradaxa)

You'll see more patients on the new anticoagulant dabigatran (Pradaxa)...and fewer taking warfarin for atrial fibrillation.

It's not just because dabigatran doesn't need monitoring. Dabigatran also prevents more strokes than warfarin...about 5 more strokes per 1000 patients per year...with a similar OVERALL bleeding risk.

Some insurers now cover it WITHOUT a prior authorization...and Canadian guidelines already recommend it OVER warfarin for A fib.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote